Eli Lilly and Co (LLY.N)
Aug 20 - Eli Lilly and Co : * Jardiance demonstrated cardiovascular (cv) risk reduction in people with type 2 diabetes at high risk for cv events * Says empa-reg outcome met its primary endpoint * Says empa-reg outcome demonstrated superiority of jardiance, when added to standard of care, in cv risk reduction * Source text for Eikon * Further company coverage
- Pharmaceutical giant Eli Lilly announced Tuesday it will shift the funding for clinical trials of an early-stage Alzheimer's treatment from the University of California San Diego to the University of Southern California. The study of solanezumab is a large part of the Alzheimer's Disease Cooperative Study, a $100 million, 70-member consortium that has been headquartered at UCSD since its inception in 1991.
July 23 - Eli Lilly and Co said its quarterly revenue rose about 1 percent, helped by demand for its new cancer and diabetes treatments and the acquisition of Novartis AG's animal health business.
DUBLIN, July 16 - Britain's Immunocore completed Europe's largest ever financing round by a private life sciences company on Thursday, raising $320 million from investors including Eli Lilly & Co, Malin and Woodford Investment Management.
* British biotech firm immunocore says secures $320 million in Europe's largest private life sciences financing
WASHINGTON - Eli Lilly & Co.'s experimental lung cancer drug necitumumab improved overall survival by an average of 1.6 months but also increased the risk of sometimes fatal blood clots, according to a preliminary review by the U.S. Food and Drug Administration.
July 7 - Eli Lilly & Co.'s experimental lung cancer drug necitumumab improved overall survival by an average of 1.6 months but also increased the risk of sometimes fatal blood clots according to a preliminary review by the U.S. Food and Drug Administration.
* Indexes up: Dow 0.06 pct, S&P 0.13 pct, Nasdaq 0.14 pct (Updates to early afternoon)
where assigned, and hit the newskey (F9 on Reuters terminals)
Thomson Reuters April 27, 2015 - Corporate Meetings for US companies for Week ahead. S&P 500 Earnings - MONTH AHEAD Dividends Non S&P 500 - Weekly Federal Reserve events ConferenceCall/Webcast - Weekly Meetings - Weekly Xtra users can see more details on conference calls & webcasts by hovering your mouse over the RIC, right click, no click on Related Co Data, now click on Co Events.
|Takeda Pharmaceutical Co Ltd (4502.T)||¥5,962||-4.00|
|Johnson & Johnson (JNJ.N)||$94.36||-0.81|
|Pfizer Inc. (PFE.N)||$32.31||-0.35|
|Novartis AG (NOVN.VX)||CHF94.70||+0.50|
|Merck & Co., Inc. (MRK.N)||$54.07||-1.30|
|Abbott Laboratories (ABT.N)||$45.64||-0.38|
|Sanofi SA (SASY.PA)||€88.17||-0.27|
|AstraZeneca plc (AZN.L)||4,120.00p||+36.00|
|GlaxoSmithKline plc (GSK.L)||1,340.50p||+9.50|
|Bristol-Myers Squibb Co (BMY.N)||$59.83||-0.78|
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (LLY). A detailed report, including free correlated market analysis, and updates.
Provider : Stock Traders Daily
Provider : Wright Reports
Provider : New Constructs, LLC
Provider : ValuEngine, Inc.
Provider : S&P Capital IQ – STARS Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.